These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31867475)

  • 41. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. c-Met expression in renal cell carcinoma with bone metastases.
    Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
    J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinicopathological and prognostic characteristics of clear cell papillary renal cell carcinoma].
    Xu YW; Zhou JC; Xie HB; Yang WP; Li L; Zhang KN; Ma KF; Gong YQ; Zhang Z; Cai L; Gong K
    Zhonghua Yi Xue Za Zhi; 2021 Dec; 101(46):3784-3788. PubMed ID: 34895417
    [No Abstract]   [Full Text] [Related]  

  • 45. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma.
    Rosette KA; Lander SM; VanOpstall C; Looyenga BD
    Am J Physiol Renal Physiol; 2021 Jul; 321(1):F33-F46. PubMed ID: 34029144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Nikpanah M; Paschall AK; Ahlman MA; Civelek AC; Farhadi F; Mirmomen SM; Li X; Saboury B; Ball MW; Merino MJ; Srinivasan R; Jones EC; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2021 Jul; 46(7):3301-3308. PubMed ID: 33688985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
    Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma.
    Huang J; Huang D; Yan J; Chen T; Gao Y; Xu D; Na R
    Cancer Med; 2020 Dec; 9(24):9409-9418. PubMed ID: 33141518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT-correlation with microvascular density.
    Marcon J; Graser A; Horst D; Casuscelli J; Spek A; Stief CG; Reiser MF; Rübenthaler J; Buchner A; Staehler M
    Eur Radiol; 2020 Jan; 30(1):1-10. PubMed ID: 31278580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology.
    Woldu SL; Weinberg AC; RoyChoudhury A; Chase H; Kalloo SD; McKiernan JM; DeCastro GJ
    Int Urol Nephrol; 2014 Nov; 46(11):2127-32. PubMed ID: 25000896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.
    Chandarana H; Rosenkrantz AB; Mussi TC; Kim S; Ahmad AA; Raj SD; McMenamy J; Melamed J; Babb JS; Kiefer B; Kiraly AP
    Radiology; 2012 Dec; 265(3):790-8. PubMed ID: 23175544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytohistopathologic hybrid renal cell carcinoma with papillary and clear cell features.
    Mai KT; Kohler DM; Roustan Delatour NL; Veinot JP
    Pathol Res Pract; 2006; 202(12):863-8. PubMed ID: 17034957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of nectin-4 in papillary renal cell carcinoma.
    Zschäbitz S; Mikuteit M; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S
    Discov Oncol; 2022 Sep; 13(1):90. PubMed ID: 36136143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
    Wang KL; Weinrach DM; Luan C; Han M; Lin F; Teh BT; Yang XJ
    Hum Pathol; 2007 Feb; 38(2):239-46. PubMed ID: 17056094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis.
    Modi PK; Singer EA
    Ann Transl Med; 2016 Apr; 4(7):143. PubMed ID: 27162793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of cortico-medullary phase contrast-enhanced MDCT and T2-weighted MR imaging in the histological subtype differentiation of renal cell carcinoma: radiology-pathology correlation.
    Halefoglu AM; Ozagari AA
    Pol J Radiol; 2021; 86():e583-e593. PubMed ID: 34876939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
    Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
    Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.